PT  - JOURNAL ARTICLE
AU  - Kumari, Santosh
AU  - Bubak, Matthew
AU  - Schoenberg, Hayden M.
AU  - Davidyan, Arik
AU  - Elliehausen, Christian J.
AU  - Kuhn, Katrin G.
AU  - VanWagoner, Timothy M.
AU  - Karaman, Rowan
AU  - Scofield, Robert Hal
AU  - Miller, Benjamin F.
AU  - Konopka, Adam R.
TI  - Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial
AID  - 10.1101/2021.10.20.21265196
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.20.21265196
4099  - http://medrxiv.org/content/early/2021/10/24/2021.10.20.21265196.short
4100  - http://medrxiv.org/content/early/2021/10/24/2021.10.20.21265196.full
AB  - The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans. While there is extensive epidemiological support for the health benefits of metformin in patient populations, it is not clear if these protective effects apply to those free of age-related disease. Our previous data in older adults without diabetes suggest a dichotomous change in insulin sensitivity and skeletal muscle mitochondrial adaptations after metformin treatment when co-prescribed with exercise. Those who entered the study as insulin sensitive had no change to detrimental effects while those who were insulin resistant had positive changes. The objective of this clinical trial is to determine if 1) antecedent metabolic health and 2) skeletal muscle mitochondrial remodeling and function mediate the positive or detrimental effects of metformin monotherapy, independent of exercise, on the metabolism and biology of aging. In a randomized, double blind clinical trial, adults free of chronic disease (n=148, 40-75 years old) are stratified as either insulin sensitive or insulin resistant based on HOMA-IR (≤2.2 or ≥2.5) and take 1500 mg/day of metformin or placebo for 12 weeks. Hyperinsulinemic-euglycemic clamps and skeletal muscle biopsies are performed before and after 12 weeks to assess primary outcomes of peripheral insulin sensitivity and mitochondrial remodeling and function. Findings from this trial will identify clinical characteristics and cellular mechanisms involved in modulating the effectiveness of metformin treatment to target aging that could inform larger phase 3 clinical trials aimed at testing aging as an indication for metformin.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04264897Funding StatementThis work is supported by National Institute of Aging Grant R01 AG064951 (BFM), the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR002373 (UWM), the Oklahoma Shared Clinical and Translational Resources, grant U54GM104938 (OUHSC), and Dexcom, Inc (ARK). The work at UWM is supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the Department of Veterans Affairs, or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Oklahoma Health Sciences Center serves as the single IRB of record and approved all study procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be available upon reasonable request to the authors